$6.91
1.45%
Downside
Day's Volatility :3.98%
Upside
2.57%
39.07%
Downside
52 Weeks Volatility :73.59%
Upside
56.65%
Period | Kala Bio Inc | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | 14.92% | 0.0% | 0.0% |
6 Months | 1.69% | 0.0% | 0.0% |
1 Year | -52.05% | 0.0% | 0.0% |
3 Years | -95.96% | -20.2% | -20.2% |
Market Capitalization | 32.0M |
Book Value | $2.37 |
Earnings Per Share (EPS) | -14.56 |
PEG Ratio | 0.0 |
Wall Street Target Price | 16.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.78% |
Return On Equity TTM | -262.61% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 1.3M |
EBITDA | -40.6M |
Diluted Eps TTM | -14.56 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -14.49 |
EPS Estimate Next Year | -7.57 |
EPS Estimate Current Quarter | -2.89 |
EPS Estimate Next Quarter | -2.86 |
What analysts predicted
Upside of 138.78%
Sell
Neutral
Buy
Kala Bio Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Kala Bio Inc | 57.39% | 1.69% | -52.05% | -95.96% | -97.44% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Kala Bio Inc | 11.21 | NA | 0.0 | -14.49 | -2.63 | -0.41 | NA | 2.37 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Kala Bio Inc | Buy | $32.0M | -97.44% | 11.21 | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Kala Bio Inc
Revenue is down for the last 2 quarters, 1.22M → 70.0K (in $), with an average decrease of 94.3% per quarter
Netprofit is down for the last 2 quarters, -8.62M → -11.80M (in $), with an average decrease of 36.9% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 113.7%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 282.5%
Baker Bros Advisors LP
Millennium Management LLC
UBS O'Connor LLC
Vanguard Group Inc
BlackRock Inc
Board of Ttees Leland Stanford Jr Univ
kala pharmaceuticals, inc. (kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based mucus penetrating particles, or mpp, technology, with an initial focus on the treatment of eye diseases. for more information, please visit kala’s website at www.kalarx.com.
Organization | Kala Bio Inc |
Employees | 43 |
CEO | Mr. Mark T. Iwicki |
Industry | Health Technology |
A Spac I Acquisition Corp
$6.91
-4.63%
Keyarch Acquisition Corp
$6.91
-4.63%
Connexa Sports Technologies Inc
$6.91
-4.63%
Us Value Etf
$6.91
-4.63%
First Wave Biopharma Inc
$6.91
-4.63%
Global X Msci Next Emerging
$6.91
-4.63%
Fat Projects Acquisition Corp
$6.91
-4.63%
Capital Link Global Fintech
$6.91
-4.63%
Applied Uv Inc
$6.91
-4.63%